The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Open accessAbstract
BACKGROUND: There is evidence that medications or vitamins that increase the levels of brain catecholamines and protect against oxidative damage may reduce the neuronal damage and slow the progression of Alzheimer's disease. METHODS: We conducted a double-blind, placebo-controlled, randomized, multicenter trial in patients with Alzheimer's disease of moderate severity. A total of 341 patients received the selective monoamine oxidase inhibitor selegiline (10 mg a day), alpha-tocopherol (vitamin E, 2000 IU a day), both selegiline and alpha-tocopherol, or placebo for two years. The primary outcome was the time to the occurrence of any of the following: death, institutionalization, loss of the ability to perform basic activities of daily living, or severe dementia (defined as a Clinical Dementia Rating of 3). RESULTS: Despite random assignment, the baseline score on the Mini-Mental State Examination was higher in the placebo group than in the other three groups, and this variable was highly predictive of the primary outcome (P<0.001). In the unadjusted analyses, there was no statistically significant difference in the outcomes among the four groups. In analyses that included the base-line score on the Mini-Mental State Examination as a covariate, there were significant delays in the time to the primary outcome for the patients treated with selegiline (median time, 655 days; P=0.012), alpha-tocopherol (670 days, P=0.001) or combination therapy (585 days, P=0.049), as compared with the placebo group (440 days). CONCLUSIONS: In patients with moderately severe impairment from Alzheimer's disease, treatment with selegiline or alpha-tocopherol slows the progression of disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“To date, none of the tested compounds have proven effective (Sano et al., 1997; Petersen et al., 2005; Pham and Plakogiannis, 2005; DeKosky et al., 2008).”
From The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease (2011) · cites this paper as Sano et al., 1997
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Following a report of success of high-dose vitamin E in keeping late-stage AD patients out of long-term care facilities longer than patients on a placebo81, other studies with vitamin E have been less impressive70,78,80.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [81]
Experimental — accuracy not yet measuredIn the citing paper
“there were no concerning safely signals or increased mortality with high-dose vitamin E. 127,128”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [127]
In the citing paper
“high-dose vitamin E (1000 IU twice daily was the regimen tested) may be considered based on results of 2 RCTs that supported approximately 20% lower rate of ADL decline over approximately 2 to 3 years; there were no concerning safely signals or increased mortality with high-dose vitamin E. 127,128”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Blessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117
Pryor, W. A. (1976) · Cited by 1,876
Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease.
Smith, C. D., Carney, J. M., Starke-Reed, P. E., Oliver, C. N., Stadtman, E. R., Floyd, R. A., & Markesbery, W. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10540 · Cited by 1,296
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group (1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,222
A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease
Knapp, M. J. (1994) · JAMA · doi:10.1001/jama.271.13.985 · Cited by 1,000
The Free Radical Theory of Aging
Harman, D. (2003) · Antioxidants and Redox Signaling · doi:10.1089/152308603770310202 · Cited by 935
Research works printed but not linked: 1
- Holm S, 1979, Scand J Stat, 6, 65
Cited by
Sorted by citations
Items 401–500 of 1,005
Neuroprotection and antioxidants
Lalkovičová, M., & Danielisová, V. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.184447 · Cited by 133
What Vitamins Should I Be Taking, Doctor?
Willett, W. C., & Stampfer, M. J. (2001) · New England Journal of Medicine · doi:10.1056/nejmcp010710 · Cited by 133
Distinction Between Preclinical Alzheimer's Disease and Depression
Visser, P. J., Verhey, F. R. J., Ponds, R., Kester, A. D. M., & JOLLES, J. (2000) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2000.tb04992.x · Cited by 133
Vitamin E for Alzheimer's disease and mild cognitive impairment
Isaac, M. G. E. K. N., Quinn, R., & Tabet, N. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002854.pub2 · Cited by 133
Vitamin E in Neurodegenerative Disorders: Alzheimer's Disease
Kontush, A., & Schekatolina, S. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1331.025 · Cited by 132
Treatment Options in Alzheimer’s Disease: Maximizing Benefit, Managing Expectations
Farlow, M. R., Miller, M. L., & Pejović, V. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000122962 · Cited by 131
Accelerated Accumulation of Amyloid β Proteins on Oxidatively Damaged Lipid Membranes
Koppaka, V., & Axelsen, P. H. (2000) · Biochemistry · doi:10.1021/bi000619d · Cited by 131
Vitamin E suppression of microglial activation is neuroprotective
Li, Y., Liu, L., Barger, S. W., Mrak, R. E., & Griffin, W. S. T. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1208 · Cited by 131
The Nitration Product 5-Nitro-γ-tocopherol Is Increased in the Alzheimer Brain
Williamson, K. S., Gabbita, S. P., Mou, S., West, M. S., Pye, Q. N., Markesbery, W. R., Cooney, R. V., Grammas, P., Reimann‐Philipp, U., Floyd, R. A., et al. (2002) · Nitric Oxide · doi:10.1006/niox.2001.0399 · Cited by 131
Nitric oxide as a physiopathological factor in neuropsychiatric disorders.
Akyol, Ö., Zoroğlu, S. S., Armutçu, F., Şahin, Ş., & Gürel, A. (2004) · PubMed · Cited by 131
Will a Healthy Lifestyle Help Prevent Alzheimer's Disease?
Pope, S. K., Shue, V. M., & Beck, C. K. (2003) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.24.100901.141015 · Cited by 132
Hanlon, J. T., Semla, T. P., & Schmader, K. E. (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13807 · Cited by 130
Alzoubi, K. H., Khabour, O. F., Salah, H. A., & Hasan, Z. A. (2013) · Physiology & Behavior · doi:10.1016/j.physbeh.2013.06.011 · Cited by 130
Improved Cognition in Alzheimer’s Disease With Short-Term D-Cycloserine Treatment
Tsai, G. E., Falk, W. E., Gunther, J. M., & Coyle, J. T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.3.467 · Cited by 129
Park, L., Anrather, J., Forster, C. L., Kazama, K., Carlson, G. A., & Iadecola, C. (2004) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/01.wcb.0000105800.49957.1e · Cited by 129
Kontush, A., Mann, U. M., Arlt, S., Ujeyl, A., Lührs, C., Müller‐Thomsen, T., & Beisiegel†, U. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00595-0 · Cited by 129
Plant-derived health: the effects of turmeric and curcuminoids.
Bengmark, S., Mesa, M. D., & Gil, Á. (2009) · PubMed · Cited by 128
Silverman, D. H. S., Gambhir, S. S., Huang, H.-W. C., Schwimmer, J., Kim, S., Small, G. W., Chodosh, J., Czernin, J. G., & Phelps, M. E. (2002) · PubMed · Cited by 128
The Effect of Long‐term Dietary Supplementation with Antioxidantsa
Meydani, M., Lipman, R. D., Han, S. N., Wu, D., Beharka, A. A., MARTIN, K. R., Bronson, R. T., Cao, G., Smith, D. E., & Meydani, S. N. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb09915.x · Cited by 128
Vitamin E and neurodegenerative diseases
Ricciarelli, R., Argellati, F., Pronzato, M. A., & Domenicotti, C. (2007) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2007.01.004 · Cited by 128
Vitamin E Imaging and Localization in the Neuronal Membrane
Monroe, E. B., Jurchen, J. C., Lee, J., Rubakhin, S. S., & Sweedler, J. V. (2005) · Journal of the American Chemical Society · doi:10.1021/ja051223y · Cited by 128
Analgesic effect of vitamin E is mediated by reducing central sensitization in neuropathic pain
Kim, H. K., Kim, J. H., Gao, X. M., Zhou, J.-L., Lee, I., Chung, K., & Chung, J. M. (2006) · Pain · doi:10.1016/j.pain.2006.01.013 · Cited by 128
Antioxidant Vitamin Supplement Use and Risk of Dementia or Alzheimer's Disease in Older Adults
Gray, S. L., Anderson, M. L., Crane, P. K., Breitner, J. C. S., McCormick, W., Bowen, J. D., Teri, L., & Larson, E. (2008) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2007.01531.x · Cited by 127
Microbial Cell Factories for Green Production of Vitamins
Wang, Y., Liu, L., Jin, Z., & Zhang, D. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.661562 · Cited by 127
Nutrition, ageing and ill health
Gariballa, S., & Sinclair, A. J. (1998) · British Journal Of Nutrition · doi:10.1017/s000711459800172x · Cited by 127
Grön, G., Bittner, D., Schmitz, B., Wunderlich, A. P., & Riepe, M. W. (2002) · Annals of Neurology · doi:10.1002/ana.10157 · Cited by 127
Neuronal death in Alzheimer’s disease and therapeutic opportunities
Donev, R., Kolev, M. V., Millet, B., & Thome, J. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00889.x · Cited by 126
SantaCruz, K. S., & Swagerty, D. L. (2001) · PubMed · Cited by 126
Butterfield, D. A., & Rukhsana Sultana, A. (2007) · Journal of Alzheimer s Disease · doi:10.3233/jad-2007-12107 · Cited by 126
Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model
Lockrow, J. P., Prakasam, A., Huang, P., Bimonte‐Nelson, H. A., Sambamurti, K., & Granholm, A. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.11.021 · Cited by 126
Antioxidant Treatment in Alzheimer's Disease: Current State
Gilgun‐Sherki, Y., Melamed, E., & Offen, D. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:21:1:1 · Cited by 126
Prospective analysis of risk factors for nursing home placement of dementia patients
Smith, G. E., O’Brien, P. C., Ivnik, R. J., Kokmen, E., & Tangalos, E. G. (2001) · Neurology · doi:10.1212/wnl.57.8.1467 · Cited by 126
Ruszkiewicz, J. A., & Albrecht, J. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2014.12.012 · Cited by 125
Vitamin E for Alzheimer's dementia and mild cognitive impairment
Farina, N., Isaac, M. G. E. K. N., Clark, A. R., Rusted, J. M., & Tabet, N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002854.pub3 · Cited by 125
Efficacy of Olanzapine in the Treatment of Psychosis in Dementia with Lewy Bodies
Cummings, J. L., Street, J. S., Masterman, D. M., & Clark, W. S. (2002) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000048636 · Cited by 124
A unifying view of ageing and disease: the double-agent theory
Lane, N. J. (2003) · Journal of Theoretical Biology · doi:10.1016/s0022-5193(03)00304-7 · Cited by 124
Vitamin E is essential for Purkinje neuron integrity
Ulatowski, L., Parker, R., Warrier, G., Sultana, R., Butterfield, D. A., & Manor, D. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2013.12.001 · Cited by 122
Yoshida, Y., Saito, Y., Jones, L. S., & Shigeri, Y. (2007) · Journal of Bioscience and Bioengineering · doi:10.1263/jbb.104.439 · Cited by 122
From Single Target to Multitarget/Network Therapeutics in Alzheimer’s Therapy
Zheng, H., Fridkin, M., & Youdim, M. B. H. (2014) · Pharmaceuticals · doi:10.3390/ph7020113 · Cited by 121
Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality
Miller, E. R., Pastor‐Barriuso, R., Dalal, D., Riemersma, R. A., Appel, L. J., & Güallar, E. (2005) · ACC Current Journal Review · doi:10.1016/j.accreview.2005.04.017 · Cited by 121
Alzheimer’s Disease, Inflammation, and the Role of Antioxidants
Sinyor, B., Mineo, J., & Ochner, C. (2020) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-200171 · Cited by 120
Azzi, A., Brigelius-Floh�, R., Kelly, F. J., Lodge, J. K., �zer, N., Packer, L., & Sies, H. (2005) · European Journal of Nutrition · doi:10.1007/s00394-005-0549-8 · Cited by 120
Diagnosis and management of Alzheimer's disease: Past, present and future ethical issues
Gauthier, S. G., Leuzy, A., Racine, É., & Rosa‐Neto, P. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.01.003 · Cited by 119
Vitamin E and Alzheimer’s disease: what do we know so far?
Browne, D., McGuinness, B., Woodside, J. V., & McKay, G. J. (2019) · Clinical Interventions in Aging · doi:10.2147/cia.s186760 · Cited by 119
Oxidative stress‐mediated down‐regulation of bcl‐2 promoter in hippocampal neurons
Pugazhenthi, S., Nesterova, A., Jambal, P., Audesirk, G. J., Kern, M., Cabell, L., Eves, E. M., Rosner, M. R., Boxer, L. M., & Reusch, J. E. B. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01606.x · Cited by 119
Measuring Alzheimer’s disease progression with transition probabilities
Neumann, P. J., Araki, S. S., Arcelus, A., Longo, A., Papadopoulos, G., Kosik, K. S., Kuntz, K. M., & Bhattacharjya, A. S. (2001) · Neurology · doi:10.1212/wnl.57.6.957 · Cited by 119
Naiki, H., Hasegawa, K., Yamaguchi, I., Nakamura, H., Gejyo, F., & Nakakuki, K. (1998) · Biochemistry · doi:10.1021/bi980550y · Cited by 119
Ryan, J. L., Croft, K. D., Mori, T. A., Wesnes, K. A., Spong, J., Downey, L. A., Kure, C., Lloyd, J., & Stough, C. K. K. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108091584 · Cited by 119
Farooqui, A. A., Litsky, M. L., Farooqui, T., & Horrocks, L. A. (1999) · Brain Research Bulletin · doi:10.1016/s0361-9230(99)00027-1 · Cited by 119
Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease
Doody, R. S., Dunn, J. K., Clark, C. M., Farlow, M., Foster, N. L., Liao, T., Gonzales, N., Lai, E., & Massman, P. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051272 · Cited by 118
Pharmacotherapy for Alzheimer's disease: progress and prospects
Palmer, A. M. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02056-4 · Cited by 118
Ayasolla, K., Khan, M., Singh, A. K., & Singh, I. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.04.007 · Cited by 118
Fatty Acid Oxidation in the Pathogenesis of Alzheimer's Disease
Montine, T. J., & Morrow, J. D. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62347-4 · Cited by 118
Euglena as a potential natural source of value-added metabolites. A review
Kottuparambil, S., Thankamony, R. L., & Agusti, S. (2019) · Algal Research · doi:10.1016/j.algal.2018.11.024 · Cited by 117
The Dynamics of Dimensions of Age-Related Disability 1982 to 1994 in the U.S. Elderly Population
Mantón, K. G., Stallard, E., & Corder, L. S. (1998) · The Journals of Gerontology Series A · doi:10.1093/gerona/53a.1.b59 · Cited by 117
Quantitative sodium MR imaging: A review of its evolving role in medicine
Thulborn, K. R. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2016.11.056 · Cited by 116
Carotenoids and Alzheimer’s Disease: An insight into therapeutic role of retinoids in animal models
Obulesu, M., Dowlathabad, M. R., & Bramhachari, P. V. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.04.004 · Cited by 116
Chen, W., Cheng, X., Chen, J., Yi, X., Nie, D., Sun, X., Qin, J., Tian, M., Jin, G., & Zhang, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088076 · Cited by 116
Stress control and human nutrition
Takeda, E., Terao, J., Nakaya, Y., Miyamoto, K., Baba, Y., Chuman, H., Kaji, R., Ohmori, T., & Rokutan, K. (2004) · The Journal of Medical Investigation · doi:10.2152/jmi.51.139 · Cited by 116
Zabel, M., Nackenoff, A., Kirsch, W. M., Harrison, F. E., Perry, G., & Schrag, M. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.12.016 · Cited by 115
Antioxidant Properties of 2,3-Dimethoxy-5-methyl- 6-(10-hydroxydecyl)-1,4-benzoquinone (Idebenone)
Mordente, A., Martorana, G. E., Minotti, G., & Giardina, B. (1998) · Chemical Research in Toxicology · doi:10.1021/tx970136j · Cited by 115
Kawas, C. H. (2003) · New England Journal of Medicine · doi:10.1056/nejmcp022295 · Cited by 115
Clinical practice guidelines for management of dementia
Shaji, K., Sivakumar, P. T., Rao, G., & Paul, N. (2018) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.224472 · Cited by 114
Oxidative injury in the nervous system
Delanty, N., & Dichter, M. A. (1998) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1998.tb07285.x · Cited by 114
Hirschman, K. B., Joyce, C. M., James, B. D., Xie, S. X., & Karlawish, J. H. (2005) · The Gerontologist · doi:10.1093/geront/45.3.381 · Cited by 114
Dementia and Alzheimer's Disease in Community-Dwelling Elders Taking Vitamin C and/or Vitamin E
Fillenbaum, G. G., Kuchibhatla, M. N., Hanlon, J. T., Artz, M. B., Pieper, C. F., Schmader, K. E., Dysken, M. W., & Gray, S. L. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1g280 · Cited by 113
Diet Quality Is Associated with Better Cognitive Test Performance among Aging Men and Women ,
Wengreen, H. J., Neilson, C., Munger, R., & Corcoran, C. (2009) · Journal of Nutrition · doi:10.3945/jn.109.106427 · Cited by 113
Alzheimer?s associated inflammation, potential drug targets and future therapies
Stuchbury, G., & M�nch, G. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0188-x · Cited by 113
Coenzyme Q10 protects retinal cells against oxidative stress in vitro and in vivo
Nakajima, Y., Inokuchi, Y., Nishi, M., Shimazawa, M., Otsubo, K., & Hara, H. (2008) · Brain Research · doi:10.1016/j.brainres.2008.06.026 · Cited by 113
Kato-Kataoka, A., Sakai, M., Ebina, R., Nonaka, C., Asano, T., & Miyamori, T. (2010) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.10-62 · Cited by 113
The Impact of Vitamin E and Other Fat-Soluble Vitamins on Alzheimer´s Disease
Grimm, M. O. W., Mett, J., & Hartmann, T. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111785 · Cited by 112
Dementia syndromes: evaluation and treatment
Scott, K. R., & Barrett, A. M. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.4.407 · Cited by 113
Current Status of Antioxidant Therapy for Alzheimer's Disease
Pitchumoni, S., & Doraiswamy, P. M. (1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb01544.x · Cited by 112
Yatin, S. M., Aksenov, M. Y., & Butterfield, D. A. (1999) · Neurochemical Research · doi:10.1023/a:1020997903147 · Cited by 112
Oxidative Stress in Alzheimer’s Disease: Should We Keep Trying Antioxidant Therapies?
Ferreira, M. E. S., de Vasconcelos, A. S., Vilhena, T. D. C., da Silva, T. L., Barbosa, A. D. S., Gomes, A. R. Q., Dolabela, M. F., & Percário, S. (2015) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0157-y · Cited by 112
Youdim, M. B. H. (2013) · Experimental Neurobiology · doi:10.5607/en.2013.22.1.1 · Cited by 111
DIETARY FACTORS AND COGNITIVE DECLINE
Smith, P. J., & Blumenthal, J. A. (2015) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2015.71 · Cited by 111
Economic considerations in the management of Alzheimer's disease
Zhu, C. W., & Sano, M. (2006) · Clinical Interventions in Aging · doi:10.2147/ciia.2006.1.2.143 · Cited by 111
Self-citationThe hemochromatosis gene affects the age of onset of sporadic Alzheimer’s disease
Sampietro, M., Caputo, L., Casatta, A., Meregalli, M., Pellagatti, A., Tagliabue, J., Annoni, G., & Vergani, C. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00219-6 · Cited by 111
Chandra, V., Jasti, J., Kaur, P., Betzel, C., Srinivasan, A., & Singh, T. P. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00473-4 · Cited by 111
Amyloid β -Protein Assembly as a Therapeutic Target of Alzheimers Disease
Yamin, G., Ono, K., Inayathullah, M., & Teplow, D. B. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208786404137 · Cited by 111
Alzheimer disease: protective factors
Nourhashémi, F., Guyonnet, S., Andrieu, S., Ghisolfi, A., Ousset, P., Grandjean, H., Grand, A., Pous, J., Vellas, B. J., & Albaréde, J. L. (2000) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.2.643s · Cited by 111
Peng, Y., Gao, P., Shi, L., Chen, L., Liu, J., & Long, J. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7763 · Cited by 110
Apoptosis: A Key in Neurodegenerative Disorders
Ekshyyan, O. Y., & Aw, T. Y. (2004) · Current Neurovascular Research · doi:10.2174/1567202043362018 · Cited by 110
Down Syndrome: Advances in Molecular Biology and the Neurosciences
Capone, G. T. (2001) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/00004703-200102000-00007 · Cited by 110
Management of Alzheimer's Disease
Grossberg, G. T., & Desai, A. K. (2003) · The Journals of Gerontology Series A · doi:10.1093/gerona/58.4.m331 · Cited by 110
Drake, J., Kański, J., Varadarajan, S., Tsoras, M., & Butterfield, D. A. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10266 · Cited by 109
The unsolved relationship of brain aging and late-onset Alzheimer disease
Kern, A., & Behl, C. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.07.016 · Cited by 108
Pisani, L., Muncipinto, G., Miscioscia, T. F., Nicolotti, O., Leonetti, F., Catto, M., Caccia, C., Salvati, P., Soto‐Otero, R., Méndez‐Álvarez, E., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9010127 · Cited by 108
Mattson, M. P., & Pedersen, W. A. (1998) · International Journal of Developmental Neuroscience · doi:10.1016/s0736-5748(98)00082-3 · Cited by 108
The Development of New Therapeutics for Alzheimer's Disease
Carter, M. D., Simms, G. A., & Weaver, D. F. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.165 · Cited by 107
Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models
Sonnen, J. A., Breitner, J. C. S., Lovell, M. A., Markesbery, W. R., Quinn, J. F., & Montine, T. J. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.04.022 · Cited by 107
Godbout, J., Berg, B. M., Kelley, K. W., & Johnson, R. W. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2003.12.017 · Cited by 107
Feldman, H., van Baelen, B., Kavanagh, S. M., & Torfs, K. (2005) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000157065.43282.bc · Cited by 107
Slow Excitotoxicity in Alzheimer's Disease
Ong, W.-Y., Tanaka, K., Dawe, G. S., Ittner, L. M., & Farooqui, A. A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121990 · Cited by 106
Mitochondrial Dynamics in Alzheimerʼs Disease
Bonda, D., Wang, X., Perry, G. L., Smith, M. A., & Zhu, X. (2010) · Drugs & Aging · doi:10.2165/11532140-000000000-00000 · Cited by 106
Wyse, Â. T. D. S., Zugno, A. I., STRECK, E. L., Matté, C., Calcagnotto, T., Wannmacher, C. M. D., & Wajner, M. (2002) · Neurochemical Research · doi:10.1023/a:1021647329937 · Cited by 106
Supplemental Use of Antioxidant Vitamins and Subsequent Risk of Cognitive Decline and Dementia
Maxwell, C. J., Hicks, M. S., Hogan, D. B., Basran, J., & Ebly, E. M. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000085074 · Cited by 105
The role of micronutrients in psychomotor and cognitive development
Grantham‐McGregor, S., & Ani, C. C. (1999) · British Medical Bulletin · doi:10.1258/0007142991902583 · Cited by 105
Vitamin E in aging, dementia, and Alzheimer's disease
Joshi, Y. B., & Praticò, D. (2012) · BioFactors · doi:10.1002/biof.195 · Cited by 105
Metadata
- Authors
- Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., Schneider, L. S., & Thal, L. J.
- Affiliations
- University of California San Diego (US)
- Harvard University (US)
- University of California, Irvine (US)
- University of South Florida (US)
- University of Southern California (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1997-04-24
- Volume
- 336
- Issue
- 17
- Pages
- 1216-1222
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2326200998
- Cited by
- 2,380
- References
- 36
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 39 · 2023: 39 · 2022: 41 · 2021: 38 · 2020: 44 · 2019: 43 · 2018: 44 · 2017: 47 · 2016: 55 · 2015: 54 · 2014: 72 · 2013: 62 · 2012: 82
- FWCI
- 118.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (U01‐AG10483, U01AG010483, U19AG010483)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, selegiline, alpha-tocopherol, vitamin E, monoamine oxidase inhibitors, combination therapy, disease progression, dementia, activities of daily living, Mini-Mental State Examination, oxidative stress, catecholamines
- MeSH terms
- Activities of Daily Living, Aged, Alzheimer Disease, Cognition, Double-Blind Method, Drug Combinations, Female, Humans, Institutionalization, Male, Mental Status Schedule, Monoamine Oxidase Inhibitors, Selegiline, Vitamin E, Proportional Hazards Models, Treatment Outcome, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
